1st Quarter - Amendment

PFIZER INC. for PFIZER INC.

Firm
Client
Income
—
Expenses
$4,430,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 17, 2026 $4,420,000 Replaced
1st Quarter - Amendment (this page) Oct 7, 2026 $4,430,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Intellectual Property Protections

LobbyistCovered position, as disclosed
FRANCISCO CARRILLO —

Contacted: HOUSE OF REPRESENTATIVES

Health Issues HCR

Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025

LobbyistCovered position, as disclosed
FRANCISCO CARRILLO —
EMILY MUELLER —
MATTHEW STROIA —
JENNIFER SWENSON WALTON —
ANGELA BOOTHE WILES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS)

Bills named: H.R. 5509 (119th), H.R. 7837 (119th), S. 2903 (119th), S. 3510 (119th)

Medicare/Medicaid MMM

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues

LobbyistCovered position, as disclosed
EMILY MUELLER —
MATTHEW STROIA —
JENNIFER SWENSON WALTON —
ANGELA BOOTHE WILES —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues

LobbyistCovered position, as disclosed
STEPHEN CLAEYS —
EMILY MUELLER —
CATHERINE ROBINSON —
MATTHEW STROIA —
JENNIFER SWENSON WALTON —
ANGELA BOOTHE WILES —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.